Noticias de CLRB_US
Noticias del mercado
Últimas noticias sobre CLRB_US — 248 novedades recientes. Análisis, balances, opiniones y cobertura de prensa.
Cellectar Biosciences (CLRB) director Andrew Gu submits initial Form 3 ownership filing
Cellectar Biosciences (CLRB) Declines 3.09% as Stock Tests Support Near $2.38 - Swing Entry Signals
Cellectar Biosciences (CLRB) Declines 3.09% as Stock Tests Support Near $2.38 - Demand Zone
Janus Henderson Group holds 9.99% of Cellectar Biosciences (CLRB)
Cellectar Biosciences (CLRB) registers 51.998M shares for resale; board seat named
Cellectar plans phase 3 trial for WM treatment after BTKi
Cellectar plans phase 3 trial for WM treatment after BTKi By Investing.com
Cellectar plans phase 3 trial for WM treatment after BTKi By Investing.com
Cellectar plans phase 3 trial for WM treatment after BTKi By Investing.com
Cellectar plans phase 3 trial for WM treatment after BTKi By Investing.com
Cellectar Biosciences to Highlight Compelling New Efficacy
Cellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/r Waldenström Macroglobulinemia at the American Society of Clinical Oncology Annual…
Cellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/r Waldenström Macroglobulinemia at the American Society of Clinical Oncology Annual…
Cellectar Biosciences (CLRB) FDA Approvals, PDUFA Dates & Drug Alerts 2026 $CLRB
Cellectar Biosciences Q1 2026 earnings preview
Cellectar Biosciences Q1 2026 earnings preview
Página 1 de 13
